KRAS and cancer: We further tested a broader panel of KRas-driven mutant (KRasG12V CFPAC-1, KRasG12C MIA PaCa-2, KRasG12V Capan-1, KRasG12T SW1990 and KRasG12C H23) and wild-type KRas (BxPC-3 and H1299) cancer cells as well as human normal peripheral blood mononuclear cell (PBMC), embryonic kidney (HEK-293), lung fibroblast (MRC-5), and liver (HL-7702) cell lines.